Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia

Medical Care

Volumn 41, Issue 2, 2003, Pages 208-217

  Pyne, Jeffrey M ^a,d   Sullivan, Greer ^a   Kaplan, Robert ^b   Williams, D Keith ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE STUDY; DEPRESSION; DISABILITY; FEMALE; HEALTH SURVEY; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOMETRY; QUALITY OF LIFE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; UNITED STATES; WORLD HEALTH ORGANIZATION;

DEPRESSIVE DISORDER; DISABILITY EVALUATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INTERVIEW, PSYCHOLOGICAL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 0037313022     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200302000-00003     Document Type: Article

References (41)

1. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
2. Meltzer D. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia. J Clin Psychiatry 1999;60(Suppl 3):32-35; discussion 36-37.
3. Revicki DA, Luce BR, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Commun Psychiatry 1990;41:850-854.
4. Davies LM, and Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38-42.
5. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638.
6. Zhang M, Owen RR, Pope SK, et al. Cost-effectiveness of clozapine monitoring after the first 6 months. Arch Gen Psychiatry 1996;53:954-958.
7. Rosenheck R, Cramer J, Allan E, et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Arch Gen Psychiatry 1999;56:565-572.
8. Sturm R, Unutzer J, and Katon W. Effectiveness research and implications for study design: sample size and statistical power. Gen Hosp Psychiatry 1999;21:274-283.
9. Awad A. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hospital and Community Psychiatry 1992;43:262-265.
10. Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51:1115-1128.
11. Kay S, Fiszbein A, and Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
12. Addington D, Addington J, and Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry 1993;163:39-44.
13. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233.
14. Zimtnerman M, Neil N, Hartung J, et al. Screening for psychiatric disorders in medical patients: A feasibility and patient acceptance study. Med Care 1994;32:603-608.
15. Kazis L, Clark J, Miller D, et al. A modified version of a short form health survey for assessing health related quality of life in veterans: the veterans health study (abstract). Ahsr Fhsr Annu Meeting Abstr Book 1994;11:15.
16. Hays R, Sherbourne C, and Mazel R. The Rand 36-item health survey 1.0. Health Econ 1993;2:217-227.
17. Kazis L. The SF-36V. Bedford VA Center for Health Quality, Outcomes, and Economic Research 1997.
18. Kazis LE, Ren XS, Lee A, et al. Health status in VA patients: results from the Veterans Health Study. Am J Med Qual 1999;14:28-38.
19. World Health O. WHO-DAS II: Disablement Assessment Schedule. Intermediate version for field trials. Geneva World Health Organization 1998.
20. Kaplan RM, and Anderson JP. The general health policy model: an integrated approach. In: Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven; 1996:309-321.
21. Kaplan RM. Quality of life assessment for cost/utility studies in cancer. Cancer Treat Rev 1993;19 Suppl A:85-96.
22. Kaplan R. Hippocratic Predicament:, afford-ability, access, and accountability in health care. San Diego, CA: Academic Press; 1993.
23. Patterson T, Kaplan R, Grant I, et al. Quality of well-being in late life psychosis. Psychiatry Res 1996;63:169-181.
24. Kerner DN, Patterson TL, Grant I, et al. Validity of the Quality of Well-Being Scale for patients with Alzheimer's disease. J Aging Health 1998;10:44-61.
25. Kaplan RM. Value judgment in the Oregon Medicaid experiment. Med Care 1994;32:975-988.
26. Rosenheck R, Cramer J, Weichun X, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-815.
27. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-897.
28. Weissman MM, Olfson M, Gameroff MJ, et al. A comparison of three scales for assessing social functioning in primary care. Am J Psychiatry 2001;158:460-466.
29. Heslegrave RJ, Awad AG, and Voruganti LN. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci 1997;22:235-243.
30. Dickerson FB, Ringel NB, and Parente F. Subjective quality of life in out-patients with schizophrenia: clinical and utilization correlates. Acta Psychiatr Scand 1998;98:124-127.
31. Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry 1996;57(Suppl 11):61-67.
32. Cohen J. A power primer. Psychol Bull 1992;112:155-159.
33. Tunis SL, Croghan TW, Heilman DK; et al. Reliability, validity, and application of the medical out-comes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 1999;37:678-691.
34. Voruganti LN, Heslegrave RJ, and Awad AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. J Psychiatry Neurosci 1997;22:267-274.
35. Heinrichs DW, Hanlon TE, and Carpenter WT, Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398.
36. Lehman AF. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry 1983;40:366-373.
37. Rosenheck R, Cramer J, Xu W, et al. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health Serv Res 1998;33(5 Ft 1):1237-1261.
38. Sullivan G, Wells KB, Morgenstern H, et al. Identifying modifiable risk factors for rehospitalization: A case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 1995;152:1749-1756.
39. EuroQol G. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
40. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002;40:113-128.
41. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: A psychometric measure of health-related quality of life. Qual Life Res 1999;8:209-224.